Metoprolol succinate and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Metoprolol succinate (metoprolol succinate), especially for people who are female, 60+ old, also take Pantoprazole, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Metoprolol succinate. It is created by eHealthMe based on reports of 64,247 people who have side effects when taking Metoprolol succinate from the FDA, and is updated regularly.

What is Metoprolol succinate?

Metoprolol succinate has active ingredients of metoprolol succinate. It is often used in high blood pressure. eHealthMe is studying from 66,933 Metoprolol succinate users. Check the latest studies of Metoprolol succinate.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 535 drugs and 467 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Jul, 09, 2026

64,247 people reported to have side effects when taking Metoprolol succinate.
Among them, 20 people (0.03%) have Second primary malignancy.

Could Metoprolol succinate cause Second primary malignancy?

Among these 20 people:

What is the gender of people who have Second primary malignancy when taking Metoprolol succinate? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Second primary malignancy when taking Metoprolol succinate? *

What are other drugs people take besides Metoprolol succinate? *

What are other side effects people have besides Second primary malignancy? *

Fatigue (feeling of tiredness): 13 people, 65.00%
Weakness: 10 people, 50.00%
Pain: 8 people, 40.00%
Fever: 8 people, 40.00%
Dyspnea (difficult or laboured breathing): 7 people, 35.00%
Diarrhea: 7 people, 35.00%
Dizziness: 6 people, 30.00%
Back Pain: 6 people, 30.00%
Chills (felling of cold): 6 people, 30.00%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 5 people, 25.00%

What are the existing conditions these people have? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 20.00%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 4 people, 20.00%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 20.00%
Breast Cancer Female: 3 people, 15.00%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 3 people, 15.00%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 2 people, 10.00%
Pain: 2 people, 10.00%
Lymphoma (cancer that begins in immune system cells): 2 people, 10.00%
Iron Deficiency: 2 people, 10.00%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Metoprolol succinate and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Metoprolol succinate:

Metoprolol succinate (66,933 reports)

Browse all side effects of Metoprolol succinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (535 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (467 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on metoprolol succinate (the active ingredients of Metoprolol succinate) and Metoprolol succinate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.